3-deazaneplanocin has been researched along with aristeromycin in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
De Clercq, E | 1 |
De Clercq, E; González, M; Jashés, M; López-Lastra, M; Sandino, A | 1 |
Kawamoto, T; Tanaka, Y; Uchiyama, N | 1 |
1 review(s) available for 3-deazaneplanocin and aristeromycin
Article | Year |
---|---|
S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents.
Topics: Adenosine; Adenosylhomocysteinase; Animals; Antiviral Agents; Hydrolases; Models, Biological; Tubercidin; Virus Replication | 1987 |
2 other study(ies) available for 3-deazaneplanocin and aristeromycin
Article | Year |
---|---|
Inhibitors of infectious pancreatic necrosis virus (IPNV) replication.
Topics: Adenosine; Adenosylhomocysteinase; Amides; Animals; Antiviral Agents; Cell Line; DNA; Foscarnet; Hydrolases; IMP Dehydrogenase; Infectious pancreatic necrosis virus; Orotidine-5'-Phosphate Decarboxylase; Pyrazoles; Ribavirin; Ribonucleosides; Ribose; Salmon; Viral Plaque Assay; Virus Replication | 1996 |
Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a.
Topics: Adenosine; Adenosylhomocysteinase; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; MicroRNAs; Prostatic Neoplasms; RNA, Small Interfering; Transcriptional Activation | 2017 |